Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.

Scientific reports - 14 Sept 2017

Manasa Justen, Varghese Vici, Pond Sergei L Kosakovsky, Rhee Soo-Yon, Tzou Philip L, Fessel W Jeffrey, Jang Karen S, White Elizabeth, Rögnvaldsson Thorsteinn, Katzenstein David A, Shafer Robert W

Abstract excerpt

Several groups have proposed that genotypic determinants in gag and the gp41 cytoplasmic domain (gp41-CD) reduce protease inhibitor (PI) susceptibility without PI-resistance mutations in protease. However, no gag and gp41-CD mutations definitively responsible for reduced PI susceptibility have been identified in individuals with virological failure (VF) while receiving a boosted PI (PI/r)-containing regimen. To...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Evolution, Molecular
Share to gag Gene Products, Human Immunodeficiency Virus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Envelope Protein gp41

Share to HIV Infections

Share to HIV Protease Inhibitors

Share to Ritonavir

Share to Selection, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 28912582
DOI: 10.1038/s41598-017-11893-8
PMCID: PMC5599673

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.PMID 28912582Read ↗

Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy.Semantic proximity Read ↗

Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations.Semantic proximity Read ↗

Analysis of near full-length genomic sequences of drug-resistant HIV-1 spreading among therapy-naïve individuals in Nagoya, Japan: amino acid mutations associated with viral replication activity.Semantic proximity Read ↗

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.Semantic proximity Read ↗

Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir.Semantic proximity Read ↗

HIV-1 Protease Evolvability is Affected by Synonymous Nucleotide RecodingSemantic proximity Read ↗

Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1Semantic proximity Read ↗

Positive selection detection in 40,000 human immunodeficiency virus (HIV) type 1 sequences automatically identifies drug resistance and positive fitness mutations in HIV protease and reverse transcriptase.Semantic proximity Read ↗

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.Semantic proximity Read ↗

Human Immunodeficiency Virus Gag and protease: partners in resistance.Semantic proximity Read ↗

Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.Semantic proximity Read ↗

Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.